Collectively, our findings uncover a metabolic-transcriptional coupling pathway in which nuclear HK2 functions as a MYC cofactor to drive glycolysis and stemness under high-glucose conditions, and they suggest that targeting HK2 may represent a rational therapeutic strategy for patients with bladder cancer and coexisting hyperglycemia or diabetes. This evidence concerns the gene MYC and urinary bladder cancer.